<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autoimmune pancreatitis: Management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autoimmune pancreatitis: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Autoimmune pancreatitis: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas G Adler, MD, FACG, AGAF, FASGE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence S Friedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H690723063"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Autoimmune pancreatitis (AIP) is an uncommon but well-established form of pancreatic inflammation. Unlike other pancreatic diseases, it typically has a dramatic response to glucocorticoid therapy. AIP can appear radiographically as a focal mass that is indistinguishable from pancreatic cancer or as a diffuse pancreatic process that can be pathognomonic for AIP. If untreated, AIP can lead to pancreatic insufficiency, fibrosis, and other complications. The initial discovery of elevated immunoglobulin G4 (IgG4) as a biomarker of AIP helped establish the disorder as distinct from other forms of chronic pancreatitis. However, it is now known that IgG4 levels are often normal in AIP and that other diseases such as pancreatic cancer may also have moderately elevated IgG4 levels.  </p><p>This topic will review the management of AIP type 1 and type 2. The clinical manifestations and diagnosis of AIP and the management of IgG4-related disease are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5657.html" rel="external">"Autoimmune pancreatitis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/121219.html" rel="external">"Treatment and prognosis of IgG4-related disease"</a>.)</p><p class="headingAnchor" id="H180565274"><span class="h1">INDUCTION OF REMISSION</span><span class="headingEndMark"> — </span>The approach to management of autoimmune pancreatitis (AIP) is based upon the manifestations of AIP and the presence of immunoglobulin G4-related disease (IgG4-RD). The goal of management is to alleviate the immediate symptoms of AIP and to prevent irreversible liver fibrosis and pancreatic exocrine and endocrine failure. Treatment may prevent progression to chronic pancreatitis [<a href="#rid1">1</a>]. However, the fibroatrophic changes that accompany the initial presentation of the disease are typically permanent [<a href="#rid1">1,2</a>]. Management of AIP is largely based upon observational studies since there have been few randomized controlled trials  (<a class="graphic graphic_algorithm graphicRef131700" href="/d/graphic/131700.html" rel="external">algorithm 1</a>). Our recommendations are largely consistent with the guidelines of the International Association of Pancreatology consensus conference for the treatment of AIP [<a href="#rid3">3-5</a>] and the Japanese consensus guidelines for treatment of AIP [<a href="#rid6">6</a>]. The management of IgG4-RD is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/121219.html" rel="external">"Treatment and prognosis of IgG4-related disease"</a>.)</p><p class="headingAnchor" id="H3508770101"><span class="h2">Indications for therapy</span></p><p class="headingAnchor" id="H376517537"><span class="h3">Symptomatic patients</span><span class="headingEndMark"> — </span>Treatment for AIP is indicated in patients with any one of the following [<a href="#rid3">3</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Pancreatic symptoms including obstructive jaundice, abdominal pain, or back pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic "other organ involvement" (OOI) associated with IgG4-RD (eg, jaundice from bile duct strictures in patients with overlapping IgG4-related sclerosing cholangitis [IgG4-SC]).</p><p></p><p class="headingAnchor" id="H2998293992"><span class="h3">Asymptomatic patients</span><span class="headingEndMark"> — </span>Indications for treatment in asymptomatic patients with AIP include one of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent pancreatic mass on imaging (eg, three to four weeks).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent liver test abnormalities (eg, two to three weeks) in a patient with bile duct obstruction or IgG4-SC, as this can lead to bacterial cholangitis, irreversible liver fibrosis, or cirrhosis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IgG4-RD with progressive subclinical lesions, potentially leading to severe, irreversible sequelae in vital organs (eg, biliary tree, kidney, aorta, mediastinum, retroperitoneum, mesentery). (See  <a class="medical medical_review" href="/d/html/121219.html" rel="external">"Treatment and prognosis of IgG4-related disease", section on 'Treatment approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Irreversible pancreatic exocrine and endocrine failure due to AIP. </p><p></p><p>Asymptomatic patients with AIP without these features require watchful waiting. About 10 to 25 percent of AIP patients improve spontaneously [<a href="#rid7">7</a>]. </p><p class="headingAnchor" id="H1747614217"><span class="h2">Glucocorticoid therapy</span><span class="headingEndMark"> — </span>For most patients requiring treatment, we recommend initial treatment with glucocorticoid monotherapy.</p><p class="headingAnchor" id="H1685483027"><span class="h3">Dose and duration</span><span class="headingEndMark"> — </span>Our approach is to initiate treatment with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 0.6 mg/kg (typically 40 mg) per day for four to six weeks [<a href="#rid3">3</a>]. Most patients demonstrate clinical and/or radiologic improvement within the first four to six weeks; many patients respond even earlier. Administration of high-dose glucocorticoids results in more rapid and successful induction of remission than conservative management [<a href="#rid3">3</a>]. Treatment may prevent progression to chronic pancreatitis [<a href="#rid1">1</a>]. </p><p>Induction therapy with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>/<a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> 20 to 30 mg/day with a minimum of 12 weeks of treatment may also achieve a response. Although lower doses of prednisolone appear to have comparable efficacy in retrospective studies, randomized trials are lacking [<a href="#rid8">8</a>]. In one retrospective, multicenter study of 65 AIP patients who were treated with one of three different prednisone regimens at the discretion of the treating clinician (low dose [10 to 20 mg daily]; medium dose [30 mg daily], and high dose [40 to 60 mg daily]), at six-month follow up, nearly all patients had complete resolution of symptoms [<a href="#rid8">8</a>]. In patients treated with 10 or 15 mg/day, this dose was maintained for at least six months. Patients treated with higher initial daily doses were continued for two to four weeks, after which the dose was tapered, usually by 5 mg per one to two weeks. </p><p class="headingAnchor" id="H309221925"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The majority of patients with AIP respond to glucocorticoids (80 to 99 percent), but patients may require a second course of treatment due to disease relapse [<a href="#rid9">9-12</a>]. (See <a class="local">'Incidence and risk factors for relapse'</a> below.)</p><p>In a retrospective study in Japan that included 563 patients with AIP, of whom 459 (82 percent) received glucocorticoids, remission rates were significantly higher in patients treated with glucocorticoids as compared with patients who did not receive glucocorticoid therapy (98 versus 74 percent) [<a href="#rid5">5</a>]. Indications for the use of glucocorticoids included obstructive jaundice (60 percent), abdominal pain (11 percent), associated extrapancreatic lesions except the biliary duct (11 percent), and diffuse enlargement of the pancreas (10 percent). In another retrospective, international multicenter study of 1064 patients (684 with type 1 AIP and 52 with type 2 AIP), remission rates in patients with type 1 and type 2 AIP who were treated with glucocorticoids were 99 and 82 percent, respectively [<a href="#rid4">4</a>]. Rates of relapse were significantly higher in patients with type 1 AIP as compared with type 2 AIP (31 versus 9 percent), and in those with associated IgG4-SC (56 versus 26 percent).</p><p class="headingAnchor" id="H3886341685"><span class="h2">Assessment of response to therapy</span></p><p class="headingAnchor" id="H2521653270"><span class="h3">Evaluation</span><span class="headingEndMark"> — </span>Most patients typically demonstrate a clinical and/or radiologic improvement within the first four to six weeks. Patients with AIP usually have a rapid and complete resolution of clinical symptoms such as abdominal pain or jaundice after initiation of glucocorticoids. To assess response to treatment, we perform imaging tests (typically computed tomography or magnetic resonance imaging, whichever was obtained initially) to evaluate for radiologic improvement (eg, a decrease in focal mass, diffuse swelling, narrowed pancreatic duct or biliary strictures) at the end of the four- to six-week induction period.  </p><p></p><p>Failure to respond to a trial of four to six weeks of glucocorticoids should raise the possibility of an alternative diagnosis. (See <a class="local">'Steroid-refractory disease'</a> below.)</p><p>Normalization of serum IgG4 levels alone is not used to assess response to therapy as serologic activity correlates poorly with clinical or radiologic remission [<a href="#rid13">13</a>]. Confirmation of histologic remission in patients with clinical and radiologic remission with treatment is not required.</p><p class="headingAnchor" id="H3658708206"><span class="h3">Patients who respond</span></p><p class="headingAnchor" id="H1336425187"><span class="h4">Glucocorticoid taper</span><span class="headingEndMark"> — </span>In patients with a clinical and radiologic response to <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>/<a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> 40 mg/day for four weeks, we gradually taper the dose by 5 mg/week over a two-month period, with the goal of discontinuing glucocorticoids entirely unless patients have a high risk of relapse. (See <a class="local">'Maintenance treatment for high relapse risk'</a> below.)</p><p>There are other alternative approaches to glucocorticoid tapers [<a href="#rid3">3</a>]. The international consensus for the treatment of AIP recommends a taper by 5 to 10 mg/day every one to two weeks until a daily dose of 20 mg is reached, followed by tapering by 5 mg every two weeks. The duration of total induction treatment should generally last 12 weeks.</p><p class="headingAnchor" id="H3553095834"><span class="h4">Inability to tolerate taper</span><span class="headingEndMark"> — </span>Patients may initially improve but have worsening of disease or "flare" before AIP is in remission. This typically occurs during glucocorticoid dose reduction or withdrawal. </p><p>Treatment options for steroid-dependent AIP include continued low-dose glucocorticoids (<a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 2.5 to 10 mg daily), thiopurines (<a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a>), and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>.</p><p class="headingAnchor" id="H3934451719"><span class="h3">Steroid-refractory disease</span><span class="headingEndMark"> — </span>Failure to respond to a trial of glucocorticoids for four to six weeks should raise the possibility of an alternative diagnosis. The lack of response to a glucocorticoid trial warrants referral for surgical exploration for pancreatic cancer. If the diagnosis of AIP is re-established, steroid-refractory patients can be treated with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. (See  <a class="medical medical_review" href="/d/html/5657.html" rel="external">"Autoimmune pancreatitis: Clinical manifestations and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H271906477"><span class="h2">Special populations</span></p><p class="headingAnchor" id="H1927452799"><span class="h3">Patients with contraindications to steroids</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> (anti-CD20 antibody) can be used as initial treatment in patients in whom glucocorticoids are contraindicated [<a href="#rid14">14,15</a>]. Other steroid-sparing agents such as thiopurines are poorly effective as single agents for induction of remission.</p><p class="headingAnchor" id="H373431821"><span class="h3">Patients with obstructive jaundice</span><span class="headingEndMark"> — </span>Obstructive jaundice is a common complication of AIP. Patients with mild jaundice (incomplete obstruction) without cholangitis can be treated with glucocorticoids alone without biliary stenting [<a href="#rid4">4,16</a>]. However, in patients with AIP and co-existing IgG4-SC as part of IgG4-RD, biliary drainage is useful to prevent biliary infection, and use of brushing and cytology can differentiate IgG4-SC from biliary malignancy [<a href="#rid3">3</a>]. </p><p>The management of biliary strictures in patients with AIP is controversial. Our recommendations are based on consensus opinion and observational studies because randomized trials are lacking. The clinical considerations and risks vary markedly among patients, as well as with the location of the strictures (including intra- and extra-hepatic biliary strictures), the extent of the strictures, and the degree of obstruction. </p><p class="headingAnchor" id="H1336570112"><span class="h1">SUBSEQUENT MANAGEMENT</span></p><p class="headingAnchor" id="H4224074908"><span class="h2">Approach based on risk of AIP relapse</span></p><p class="headingAnchor" id="H1926454129"><span class="h3">Incidence and risk factors for relapse</span><span class="headingEndMark"> — </span>Relapse is defined as recurrent clinical, radiologic, or biochemical evidence of disease activity that occurs <strong>after </strong>complete remission is achieved. Abdominal pain as a standalone symptom in the absence of pancreatic inflammation and elevation of immunoglobulin G4 (IgG4) without concomitant biochemical or radiologic change does not represent relapse and does not necessitate retreatment.</p><p>Type 2 AIP has no risk of recurrence and maintenance treatment is not needed. </p><p>Rates of relapse are significant in patients with type 1 autoimmune pancreatitis (AIP) and in those with associated IgG4-related sclerosing cholangitis (IgG4-SC) [<a href="#rid17">17</a>]. In a retrospective multicenter study, 56 percent of patients with type 1 AIP relapsed within one year, 76 percent within two years, and 92 percent within three years [<a href="#rid5">5</a>]. In another retrospective, international multicenter study of 1064 patients (684 with type 1 AIP and 52 with type 2 AIP), remission rates in patients with type 1 and type 2 AIP were 99 and 82 percent, respectively [<a href="#rid4">4</a>]. Rates of relapse were significantly higher in patients with type 1 AIP as compared with type 2 AIP (31 versus 9 percent), and in those with associated IgG4-SC (56 versus 26 percent).</p><p>Patients are considered at high risk of AIP relapse if they have one or more of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Type 1 AIP with diffuse enlargement of the pancreas</p><p class="bulletIndent1"><span class="glyph">●</span>More than two other organs involvement (OOIs) or association with proximal IgG4-SC before treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Delayed radiologic remission with treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Persistently high serum IgG4 (&gt;2 times upper limit of normal) after treatment</p><p></p><p>Patients are considered at low risk of relapse if they have low disease activity, such as involvement in the pancreas alone with segmental/focal lesion without any OOIs, and complete radiologic remission with rapid normalization of IgG/IgG4 levels in response to glucocorticoids [<a href="#rid3">3</a>]. </p><p class="headingAnchor" id="H1991745877"><span class="h3">Maintenance treatment for high relapse risk</span><span class="headingEndMark"> — </span>In patients at high risk of relapse, we suggest maintenance treatment to reduce the risk of relapse [<a href="#rid18">18</a>]. Treatment options include low-dose glucocorticoids (<a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 2.5 to 10 mg/day for one to three years or indefinitely), immunomodulators (<a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> [2 mg/kg daily] or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil [750 mg twice daily]), or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid3">3,14</a>]. </p><p>The choice of agent depends upon individual patient factors (presence of IgG4 disease), cost/insurance considerations, and availability. We generally use <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> as a first line of therapy for maintenance treatment of AIP and use <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in patients with IgG4-RD or resistance to or side effects from other treatments, including glucocorticoids and immunomodulators [<a href="#rid14">14,19,20</a>]. Rituximab has been successfully used to treat patients with IgG4-RD, including type 1 AIP, with resistance to or side effects from other treatments, including glucocorticoids and immunomodulators, and for IgG4-SC with AIP [<a href="#rid14">14,19,20</a>]. However, rituximab is more expensive than glucocorticoids and immunomodulators and may not be available or covered by insurance. </p><p>Maintenance treatment reduces relapse rates in patients with AIP. However, evidence to support the use of steroid-sparing agents (eg, immunomodulators and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>) is largely from retrospective studies, and randomized trials comparing steroid-sparing agents to glucocorticoids are lacking. In retrospective studies, relapse-free survival is similar in those treated with glucocorticoids plus immunomodulators as compared with those treated with steroids alone. The following studies are illustrative of the efficacy of maintenance therapy in patients with AIP:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized controlled trial to determine if maintenance treatment reduced type 1 AIP relapse rates, 49 patients with AIP were randomly assigned to a <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> maintenance therapy (5 to 7.5 mg/day) for three years or cessation of therapy by tapering prednisone and discontinuing it at 26 weeks [<a href="#rid18">18</a>]. Relapse rates within three years were significantly lower in patients assigned to prednisone maintenance as compared with the treatment cessation (23 versus 58 percent). There were no serious corticosteroid-related complications that required discontinuation of treatment during the study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A multicenter international study of 1064 patients with AIP (978 with type 1 and 86 with type 2 AIP) evaluated long-term outcomes of AIP [<a href="#rid4">4</a>]. Patients were treated with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> at a dose of 30 to 40 mg/day, with tapering by 5 to 10 mg every one to two weeks. Asian centers used maintenance low-dose prednisone 2.5 to 5.0 mg/day for six months to three years. North American studies did not use maintenance glucocorticoid therapy but rather used immunomodulator drugs (ie, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> 2 mg/kg for one to three years). Successful remission was induced in 681 of 684 type 1 AIP patients (99.6 percent) and 48 of 52 patients with type 2 AIP (92 percent). Disease relapse occurred in 245 of 684 type 1 patients (36 percent), but only 8 of 52 patients (15 percent) with type 2 AIP. A higher proportion of relapses in steroid-treated patients occurred after glucocorticoids had been discontinued (67 percent) as compared to during tapering (15 percent) or during maintenance glucocorticoid therapy (18 percent). In the management of relapse, glucocorticoids were successful in 201 of 210 patients (95 percent), and azathioprine was successful in 56 of 68 patients (85 percent). A small number of patients responded to <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a>, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, or <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study included 116 patients with type 1 AIP who were initially treated with glucocorticoids [<a href="#rid15">15</a>]. During a median follow-up of 47 months, 52 patients experienced 76 relapse episodes. The first relapse was treated with another course of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> in 24 patients and with prednisone and an immunomodulator in 27 patients. Failure or intolerance of immunomodulator therapy occurred in 17 patients (45 percent). Of the patients with glucocorticoids or immunomodulator intolerance/resistance who were treated with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, 10 of 12 (83 percent) achieved complete remission and had no relapse. Of note, the relapse-free survival was similar in patients treated with glucocorticoids plus an immunomodulator and those treated with glucocorticoids alone. Rituximab was effective in the treatment of both immunomodulator-resistant and steroid-intolerant patients.</p><p></p><p class="headingAnchor" id="H2429226971"><span class="h3">Watchful waiting for low risk of relapse</span><span class="headingEndMark"> — </span>We monitor patients at low risk of relapse with watchful waiting. This consists of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients are advised to report any new symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical and laboratory evaluation should be performed every six months, including a complete blood count and blood chemistries.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Periodic imaging, for example, after four to six weeks, at six months, and then based on clinical progression and concern for recurrence or to evaluate other possible etiologies. </p><p></p><p class="headingAnchor" id="H1599594230"><span class="h2">Management of relapse</span><span class="headingEndMark"> — </span>Relapse can be treated with the glucocorticoid therapy if it was successful for initial induction of remission. (See <a class="local">'Dose and duration'</a> above.)</p><p>For patients who do not respond to glucocorticoids, steroid-sparing agents (immunomodulators or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>) are an alternative [<a href="#rid21">21</a>]. Thiopurines and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil require overlap with glucocorticoids for six to eight weeks. Glucocorticoids are withdrawn only when AIP is in remission. Rituximab has also been successfully used to treat patients with IgG4-RD, including type 1 AIP with resistance to or side effects of glucocorticoids or immunomodulators [<a href="#rid15">15,21</a>].</p><p>For patients with more than one relapse, glucocorticoids (<a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 2.5 to 10 mg daily) or steroid-sparing agents (immune-modulators or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>) are used as maintenance treatment. (See <a class="local">'Maintenance treatment for high relapse risk'</a> above.)</p><p class="headingAnchor" id="H4250820537"><span class="h1">MONITORING FOR LONG-TERM COMPLICATIONS</span><span class="headingEndMark"> — </span>Patients with AIP can develop pancreatic exocrine and endocrine insufficiency (diabetes mellitus). Risk factors for developing diabetes mellitus include advanced age and long duration of disease resulting in extensive parenchymal atrophy [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H348451986"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112065.html" rel="external">"Society guideline links: Chronic pancreatitis and pancreatic exocrine insufficiency"</a> and  <a class="medical medical_society_guidelines" href="/d/html/117964.html" rel="external">"Society guideline links: IgG4-related disease"</a>.)</p><p class="headingAnchor" id="H4008613812"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment for autoimmune pancreatitis (AIP) is indicated in patients with any one of the following: </p><p></p><p class="bulletIndent1">Symptomatic patients with: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pancreatic symptoms including obstructive jaundice, abdominal pain, or back pain.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptomatic "other organ involvement" (OOI) associated with IgG4-related disease (IgG4-RD; eg, jaundice from bile duct strictures in patients with overlapping IgG4-related sclerosing cholangitis [IgG4-SC]). </p><p></p><p class="bulletIndent1">Asymptomatic patients with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent pancreatic mass on imaging (eg, three to four weeks).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent liver test abnormalities (eg, two to three weeks) in a patient with bile duct obstruction or IgG4-SC that may lead to bacterial cholangitis or irreversible liver fibrosis and cirrhosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IgG4-RD with progressive subclinical lesions, potentially leading to severe, irreversible sequelae in vital organs (eg, biliary tree, kidney, aorta, mediastinum, retroperitoneum, mesentery). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Irreversible pancreatic exocrine and endocrine failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with AIP and an indication for treatment, we recommend initial treatment with glucocorticoids as compared with watchful waiting (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). Our approach is to initiate treatment with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> at a dose of 40 mg per day for four to six weeks. Toward the end of the four- to six-week induction period, we perform repeat imaging tests (typically computed tomography or magnetic resonance imaging) to evaluate for radiologic improvement (eg, a decrease in focal mass, diffuse swelling, narrowed pancreatic duct or biliary strictures). Most patients destined to respond demonstrate clinical and/or radiologic improvement within the first four to six weeks. Failure to respond in this timeframe should raise the possibility of alternative diagnoses. (See <a class="local">'Glucocorticoid therapy'</a> above and <a class="local">'Steroid-refractory disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with a clinical and radiologic response to <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>/<a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a>, we gradually taper the dose by 5 mg/week with a planned reduction over a two-month period, with the goal of discontinuing glucocorticoids entirely unless the patient has a high risk of relapse. (See <a class="local">'Glucocorticoid taper'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients are considered at high risk of AIP relapse if they have one or more of the following (see <a class="local">'Incidence and risk factors for relapse'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Type 1 AIP with diffuse enlargement of the pancreas</p><p class="bulletIndent2"><span class="glyph">•</span>More than two OOIs or association with proximal IgG4-SC before treatment</p><p class="bulletIndent2"><span class="glyph">•</span>Delayed radiologic remission with treatment</p><p class="bulletIndent2"><span class="glyph">•</span>Persistently high serum IgG4 (&gt;2 times upper limit of normal) after treatment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients at high risk of AIP relapse, we suggest maintenance treatment to reduce the risk of relapse rather than watchful waiting (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Maintenance treatment options include low-dose glucocorticoids, immunomodulators (<a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil), or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>  (<a class="graphic graphic_algorithm graphicRef131700" href="/d/graphic/131700.html" rel="external">algorithm 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients without IgG4-RD, we suggest <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> as a first line of therapy for maintenance treatment of AIP as compared to <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The basis for our choice of treatment is the lower cost and wider availability of azathioprine in addition to our familiarity with its use. However, low-dose glucocorticoids and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil are reasonable treatment options in these patients. (See <a class="local">'Maintenance treatment for high relapse risk'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with IgG4-RD, we use <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> for maintenance treatment of AIP. (See  <a class="medical medical_review" href="/d/html/121219.html" rel="external">"Treatment and prognosis of IgG4-related disease", section on 'Maintenance therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We monitor patients at low risk of relapse with watchful waiting. Patients are advised to report new AIP-related symptoms and require periodic clinical evaluation, laboratory testing, and abdominal imaging. (See <a class="local">'Watchful waiting for low risk of relapse'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who relapse can be managed with a repeat course of glucocorticoids. For patients who do not respond to glucocorticoids, steroid-sparing agents (immunomodulators or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>) are an alternative. In patients with more than one relapse, glucocorticoids or a steroid-sparing agent (immunomodulator or rituximab) are used as maintenance treatment. (See <a class="local">'Management of relapse'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with AIP can develop pancreatic exocrine and endocrine insufficiency (diabetes mellitus). Risk factors for developing diabetes mellitus include advanced age and long duration of disease resulting in extensive parenchymal atrophy. (See <a class="local">'Monitoring for long-term complications'</a> above.)</p><p></p><p class="headingAnchor" id="H3236958610"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David C Whitcomb, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kuraishi Y, Uehara T, Watanabe T, et al. Corticosteroids prevent the progression of autoimmune pancreatitis to chronic pancreatitis. Pancreatology 2020; 20:1062.</a></li><li><a class="nounderline abstract_t">Maruyama M, Arakura N, Ozaki Y, et al. Type 1 autoimmune pancreatitis can transform into chronic pancreatitis: a long-term follow-up study of 73 Japanese patients. Int J Rheumatol 2013; 2013:272595.</a></li><li><a class="nounderline abstract_t">Okazaki K, Chari ST, Frulloni L, et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology 2017; 17:1.</a></li><li><a class="nounderline abstract_t">Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013; 62:1771.</a></li><li><a class="nounderline abstract_t">Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58:1504.</a></li><li><a class="nounderline abstract_t">Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol 2014; 49:961.</a></li><li><a class="nounderline abstract_t">Kubota K, Kamisawa T, Hirano K, et al. Clinical course of type 1 autoimmune pancreatitis patients without steroid treatment: a Japanese multicenter study of 97 patients. J Hepatobiliary Pancreat Sci 2018; 25:223.</a></li><li><a class="nounderline abstract_t">Buijs J, van Heerde MJ, Rauws EA, et al. Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis. Pancreas 2014; 43:261.</a></li><li><a class="nounderline abstract_t">Kamisawa T, Egawa N, Nakajima H, et al. Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. Am J Gastroenterol 2003; 98:2694.</a></li><li><a class="nounderline abstract_t">Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007; 56:1719.</a></li><li><a class="nounderline abstract_t">Moon SH, Kim MH, Park DH, et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut 2008; 57:1704.</a></li><li><a class="nounderline abstract_t">Ito T, Nakano I, Koyanagi S, et al. Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy. Dig Dis Sci 1997; 42:1458.</a></li><li><a class="nounderline abstract_t">Majumder S, Takahashi N, Chari ST. Autoimmune Pancreatitis. Dig Dis Sci 2017; 62:1762.</a></li><li><a class="nounderline abstract_t">Majumder S, Mohapatra S, Lennon RJ, et al. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease. Clin Gastroenterol Hepatol 2018; 16:1947.</a></li><li><a class="nounderline abstract_t">Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013; 62:1607.</a></li><li><a class="nounderline abstract_t">Bi Y, Hart PA, Law R, et al. Obstructive jaundice in autoimmune pancreatitis can be safely treated with corticosteroids alone without biliary stenting. Pancreatology 2016; 16:391.</a></li><li><a class="nounderline abstract_t">Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2009; 7:1089.</a></li><li><a class="nounderline abstract_t">Masamune A, Nishimori I, Kikuta K, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut 2017; 66:487.</a></li><li><a class="nounderline abstract_t">Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology (Oxford) 2020; 59:iii123.</a></li><li><a class="nounderline abstract_t">Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015; 74:1171.</a></li><li><a class="nounderline abstract_t">Soliman H, Vullierme MP, Maire F, et al. Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective. United European Gastroenterol J 2019; 7:1073.</a></li></ol></div><div id="topicVersionRevision">Topic 130656 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32800575" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Corticosteroids prevent the progression of autoimmune pancreatitis to chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23762066" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Type 1 autoimmune pancreatitis can transform into chronic pancreatitis: a long-term follow-up study of 73 Japanese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28027896" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : International consensus for the treatment of autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23232048" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19398440" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Standard steroid treatment for autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24639058" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29430861" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical course of type 1 autoimmune pancreatitis patients without steroid treatment: a Japanese multicenter study of 97 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24518506" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14687819" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17525092" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18583399" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9246047" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28365915" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Autoimmune Pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29526692" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22936672" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27107633" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Obstructive jaundice in autoimmune pancreatitis can be safely treated with corticosteroids alone without biliary stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19345283" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27543430" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32348524" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : IgG4-related disease: a clinical perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25667206" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rituximab for IgG4-related disease: a prospective, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31662864" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
